Background
Methods
Results
Case | Age (years old) | M/F | Tumor | Bev (cycles) | Lesion | Location | Radiotherapy | Bev from RT (month) | Reduction Rate | Outcome | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
FLAIR ( %) | Gd ( %) | Radiological | Clinical | |||||||||
Case 1 | 70 | F | anaplastic | 4 | Tumor 1 (non-irradiated) | R frontal (cranial) | N/A | −71 | 198 | Progression | Improved L hemiparesis | |
Tumor 2 (non-irradiated) | R frontal (caudal) | N/A | 126 | Progression | ||||||||
Tumor 3 | R frontal | SRT 32Gy | 8 | −89 | Response | |||||||
Tumor 4 | R frontotemporal | SRS 23Gy/SRS 20Gy/ SRS 22Gy/ SRT 33Gy | 3 | 7 | Stable | |||||||
Case 2 | 52 | M | anaplastic | 3 | Tumor 5 | occipital | SRS 14Gy/ SRS 14Gy/ SRT 25.5Gy/BNCT | 13 | −47 | −10 | Stable | Unchanged dizziness and visual disturbance |
Tumor 6 | L temporal | SRT 27Gy | 20 | −79 | Response | |||||||
Tumor 7 (non-irradiated) | R temporal | N/A | −5 | Stable | ||||||||
Tumor 8 | L tentorial edge | SRS 20Gy | 2.5 | −55 | Response | |||||||
Case 3 | 76 | F | atypical | 6 | Tumor 9 | parasagittal | SRT 24Gy/ BNCT | 8 | −29 | 0 | Stable | Unchanged L hemiparesis |
Case 4 | 52 | M | grade I | 3 | Tumor 10 | petroclival | GKR 14Gy/RT 30Gy/GKR 14Gy | 5.5 | −33 | −14 | Stable | Improved R hemiparesis and L ataxia |
Case 5 | 69 | F | grade I | 3 | Tumor 11 | parasagittal | SRS/ SRS | 13 | −90 | −47 | Stable | Improved gait disturbance |
Case 6 | 46 | F | anaplastic | 6 | Tumor 12 | frontal base | EBRT 60Gy/ BNCT/BNCT | 4 | −45 | −48 | Stable | Unchanged cognitive dysfunction |
Tumor 13 | orbit | BNCT/BNCT | 4 | −65 | Respose | |||||||
Tumor 14 | infratemporal | BNCT/BNCT | 4 | 12 | Stable | |||||||
Tumor 15 | frontal convexity | EBRT 60Gy/ BNCT/BNCT | 4 | 19 | Stable |
Patients | Age (years old) | Gender | Tumor | Bevacizumab (cycles) | Lesion | Location | Radiotherapy | Bev from RT (month) | Response rate ( %) | Radiological assessment |
---|---|---|---|---|---|---|---|---|---|---|
Case 2 | 52 | M | anaplastic | 3 | Necrosis 1 | occipital | SRS 14Gy/ SRS 14Gy/ SRT 25.5Gy/BNCT | 13 | −100 | Response |
Case 3 | 76 | F | atypical | 6 | Necrosis 2 | parasagittal | SRT 24Gy/ BNCT | 8 | −65 | Response |
Case 5 | 69 | F | grade I | 3 | Necrosis 3 | parasagittal | SRS/ SRS | 13 | −76 | Response |
Case 6 | 46 | F | anaplastic | 6 | Necrosis 4 | frontal | EBRT 60Gy/ BNCT/BNCT | 4 | −51 | Response |
Discussion
Authors | Tumor | Prior Tx | Bevacizumab | Treatment duration | Radiological assessment | Response | PFS/OS | Toxicity |
---|---|---|---|---|---|---|---|---|
Putchner MJA, et al. 2010 [4] | 1 Anaplstic | 60Gy RT | 10 mg/kg every 2 weeks | 6 months | N/A | 1 PR | N/A | hypertension |
Goutagny S, et al. 2011 [17] | 7 tumors in NF2 pts | none | 5 mg/kg Every 2 weeks | 15 months | volume | 1 tumor: 22 % decrease | N/A | No mention |
6 tumors N/C | ||||||||
Lou E, et al. 2012 [5] | 5 GI | RT: 12/14 | 10 mg/kg very 2 weeks | 0.5–29.5 months | RANO | 0 CR | mPFS: 17.9 months | Tumoral hemorrhage |
5 GII | CT: 11/14 | 1 PR | PFS-6: 85.7 % | G4 intestinal perforation | ||||
3 GIII | 11 SD | G5 pneumonia/sepsis | ||||||
1 unk | 2 PD | |||||||
Nayak L, et al. 2012 [18] | 6 GII | RT: 15/15 | 10 mg/kg every 2 weeks | 9 doses (1–19 doses) | RANO | 0 CR | mPFS: 26 weeks | G1 Intratumoral hemorrhage |
9 GIII | CT: 7/15 | 0 PR | mOS: 15 months | G2 fatigue | ||||
15 SD | ||||||||
Nunes FP, et al. 2013 [19] | 48 tumors in 15 NF2 pts | 5 mg/kg every 2 weeks | Response: 20 % reduction | Tumor: 29 % response | Per-tumor | 4 G3 events | ||
Progression: 20 % increase | Patients | PFS-6: 85 % | 2 G4 events (wound healing problems) | |||||
7 % response | Per-patient | |||||||
PFS-6: 93 % | ||||||||
Boström JP, et al. 2014 [20] | 1 GIII | 60Gy RT | 5 mg/kg every 2 weeks | 2 months | N/A | Stable and growing | N/A | No mention |
35Gy SRT |